The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Using 124I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71.
John F. Gerecitano
Research Funding - Samus Therapeutics
Shanu Modi
No relevant relationships to disclose
Devika Gajria
No relevant relationships to disclose
Tony Taldone
No relevant relationships to disclose
Mary Alpaugh
No relevant relationships to disclose
Erica Gomes DaGama
No relevant relationships to disclose
Mohammad Uddin
No relevant relationships to disclose
Gabriela Chiosis
Employment or Leadership Position - Samus Therapeutics (U)
Jason Stuart Lewis
No relevant relationships to disclose
Steven M. Larson
No relevant relationships to disclose
Naga Vara Kishore Pillarsetty
No relevant relationships to disclose
Komal L. Jhaveri
Consultant or Advisory Role - Samus Therapeutics
Brian Krichevsky
No relevant relationships to disclose
Mei Hsuan Chen
No relevant relationships to disclose
Payal Dixit
No relevant relationships to disclose
Mark Dunphy
Research Funding - Samus Therapeutics